Reckitt Benckiser shells $1.4B to set­tle US probe; NICE backs di­a­betes, pso­ri­a­sis treat­ments

→ British group Reckitt Benckiser (RB) has agreed to pay the US De­part­ment of Jus­tice (DoJ) and the Fed­er­al Trade Com­mis­sion $1.4 bil­lion to re­solve a sweep­ing in­ves­ti­ga­tion in­to the sales and mar­ket­ing prac­tices of the opi­oid ad­dic­tion treat­ment, Sub­ox­one film, sold by its for­mer pre­scrip­tion phar­ma­ceu­ti­cals busi­ness In­di­v­ior, which was spun out in 2014. In April, In­di­v­ior was charged by the DoJ for claim­ing the prod­uct was more ef­fec­tive and safer than ri­val drugs, de­spite the lack of ev­i­dence sup­port­ing that claim.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.